ERBB2 and familial pancreatic carcinoma: Tmab-mediated ADCC against the HER2-high-expressing cell line Capan-1 was potent without the addition of αCD137 mAb and independent of the FcγRIIIA polymorphism, indicating the clinical potential of Tmab for treating this type of pancreatic cancer.